Notícias e Atividades da Marker Therapeutics

Marker Therapeutics é uma empresa listada sob o símbolo MRKR (US).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Marker Therapeutics

• Juan Vera, Chief Executive Officer
• David Eansor, Director
• Steve Elms, Director

Recentes movimentos de executivos em Marker Therapeutics

• Kathryn Penkus Corzo, ingressou na Companhia como Director  (Notícia publicada em 6 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Marker Therapeutics.

Marker Therapeutics possui 2.429 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Tempus has announced the acquisition of Personalis  (publicado em 20 de julho de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Marker Therapeutics

• Marker Therapeutics Reports Q1 2022 Operating and Financial Results | Marker Therapeutics, Inc.
• Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting | Marker Therapeutics, Inc.
• Press Releases | Marker Therapeutics, Inc.
• Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf | Marker Therapeutics, Inc.
• Marker Therapeutics to Present at Three Upcoming September Investor Conferences - Marker Therapeutics, Inc.
• Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas - Marker Therapeutics, Inc.
• Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results - Marker Therapeutics, Inc.
• Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility - Marker Therapeutics, Inc.
• Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML - Marker Therapeutics, Inc.
• Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference - Marker Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Marker Therapeutics

• Marker Therapeutics na Wikipedia, Google News e Yahoo Finance
• Marker Therapeutics na LinkedIn, X (Twitter) e YouTube